Ketamine for refractory depression: Save the best for last?

Nigam, Kabir; King, Franklin; Espi Forcen, Fernando

Nigam, Kabir; King, Franklin; Espi Forcen, Fernando.

Afiliación

Nigam K; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
King F; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Espi Forcen F; Department of Psychiatry, McLean Hospital, Belmont, MA, USA.

J Psychopharmacol ; : 2698811241282646, 2024 Sep 20.

Article en En | MEDLINE | ID: mdl-39302092

ABSTRACT

ABSTRACT

Ketamine has recently been shown to be non-inferior to electroconvulsive therapy (ECT), one of psychiatry's most effective treatments for depression. Given the novelty of ketamine as well as its interventional nature, ketamine is currently viewed as an alternative to ECT and as such, considered a third-line agent for treatment-refractory depression. However, available data suggest that ketamine carries a low side-effect burden and is better tolerated than many second-line augmentation strategies for depression. With this combination of higher efficacy and lower side-effect burden in conjunction with what is known about treatment outcomes in relation to the duration of untreated illness, it is in the best interest of patients for the field of psychiatry to evaluate ketamine as a second-line augmentation strategy for refractory depression.

Palabras clave

Ketamine; algorithm; augmentation; pharmacology; treatment-resistant depression

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Psychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google